1. Home
  2. ELVN vs IGIC Comparison

ELVN vs IGIC Comparison

Compare ELVN & IGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • IGIC
  • Stock Information
  • Founded
  • ELVN 2016
  • IGIC 2001
  • Country
  • ELVN United States
  • IGIC Jordan
  • Employees
  • ELVN N/A
  • IGIC N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • IGIC Property-Casualty Insurers
  • Sector
  • ELVN Health Care
  • IGIC Finance
  • Exchange
  • ELVN Nasdaq
  • IGIC Nasdaq
  • Market Cap
  • ELVN 1.2B
  • IGIC 1.1B
  • IPO Year
  • ELVN 2020
  • IGIC N/A
  • Fundamental
  • Price
  • ELVN $21.64
  • IGIC $23.29
  • Analyst Decision
  • ELVN Strong Buy
  • IGIC Buy
  • Analyst Count
  • ELVN 5
  • IGIC 2
  • Target Price
  • ELVN $41.20
  • IGIC $31.50
  • AVG Volume (30 Days)
  • ELVN 608.9K
  • IGIC 142.7K
  • Earning Date
  • ELVN 08-12-2025
  • IGIC 08-05-2025
  • Dividend Yield
  • ELVN N/A
  • IGIC 0.43%
  • EPS Growth
  • ELVN N/A
  • IGIC 1.83
  • EPS
  • ELVN N/A
  • IGIC 2.73
  • Revenue
  • ELVN N/A
  • IGIC $537,909,000.00
  • Revenue This Year
  • ELVN N/A
  • IGIC $6.05
  • Revenue Next Year
  • ELVN N/A
  • IGIC $7.01
  • P/E Ratio
  • ELVN N/A
  • IGIC $8.73
  • Revenue Growth
  • ELVN N/A
  • IGIC 5.21
  • 52 Week Low
  • ELVN $13.30
  • IGIC $14.86
  • 52 Week High
  • ELVN $30.03
  • IGIC $27.76
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 59.97
  • IGIC 50.63
  • Support Level
  • ELVN $21.80
  • IGIC $23.21
  • Resistance Level
  • ELVN $21.34
  • IGIC $24.24
  • Average True Range (ATR)
  • ELVN 1.32
  • IGIC 0.49
  • MACD
  • ELVN 0.18
  • IGIC 0.04
  • Stochastic Oscillator
  • ELVN 85.90
  • IGIC 49.20

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

About IGIC International General Insurance Holdings Ltd.

International General Insurance Holdings Ltd is an international specialist commercial insurer and a reinsurer, underwriting a diverse portfolio of specialty lines. The company operates in a portfolio of Energy, Property, Construction, Engineering, Ports and terminals, Financial Institutions, General Aviation, Professional Indemnity, Casualty, Directors and Officers, Political Violence, Forestry, and Treaty Reinsurance. Its operating segment includes Specialty Longtail; Specialty Short tail and Reinsurance.

Share on Social Networks: